TOP > 外国特許検索 > NUCLEIC ACID AND COMPOSITION FOR TREATING TUMORS, INCLUDING BRAIN TUMORS

NUCLEIC ACID AND COMPOSITION FOR TREATING TUMORS, INCLUDING BRAIN TUMORS NEW

外国特許コード F180009315
整理番号 (S2016-0863-N0)
掲載日 2018年1月24日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP024223
国際公開番号 WO 2018003988
国際出願日 平成29年6月30日(2017.6.30)
国際公開日 平成30年1月4日(2018.1.4)
優先権データ
  • 特願2016-131073 (2016.6.30) JP
発明の名称 (英語) NUCLEIC ACID AND COMPOSITION FOR TREATING TUMORS, INCLUDING BRAIN TUMORS NEW
発明の概要(英語) This application provides a pharmaceutical composition for treatment or prevention in a subject having a tumor that expresses the LINC00461 gene characterized by including as an active ingredient a nucleic acid that suppresses the expression of the LINC00461 gene, and an antitumor nucleic acid that suppresses the expression of the LINC00461 gene.
特許請求の範囲(英語) [claim1]
1. A nucleic acid that suppresses the expression of gene LINC00461 effectiveness and comprises the following components, the subject having a tumor gene expressed in a pharmaceutical composition for treating or preventing.
[claim2]
2. Wherein the nucleic acid, RNA transcription of the gene LINC00461 with respect to the body, siRNA, a precursor thereof RNA, antisense RNA, modified or RNA, or anti-sense DNA, alternatively, the siRNA or its precursor DNA or RNA encoding said antisense DNA and a vector that contains, a pharmaceutical composition according to claim 1.
[claim3]
3. Wherein the nucleic acid, RNA sequence of SEQ ID NO:37 150 and 1 of the transfer body position between positions of the base sequence, the nucleotide sequence of the 700 - position between position 1620, position 3050 or position 3560 and between the base sequence of a target, a pharmaceutical composition according to claim 1 or 2.
[claim4]
4. Wherein the nucleic acid base sequence to target, is selected from the group consisting of SEQ ID NO:25-34 characterized in that, a pharmaceutical composition according to claim 3.
[claim5]
5. Wherein the nucleic acid, RNA or modified siRNA below: (a) SEQ ID NO:5 of SEQ ID NO:6 and the antisense strand consists of a sequence of the sense strand siRNA RNA or modifications thereof, 7 (b) for the antisense strand sequences to a sequence number of the sense strand siRNA sequence 8 or modified RNA, 9 sequence (c) for the antisense strand sequence of either the sense strand sequence of SEQ ID NO:10 siRNA RNA or modifications thereof, 11 (d) for the antisense strand sequences to a sequence number of the sense strand siRNA sequence 12 or modified RNA, 13 (e) for the antisense strand sequences to a sequence number of the sense strand siRNA sequence 14 or modified RNA, (f) for the antisense strand sequence SEQ ID NO:15 of either the sense strand sequence of SEQ ID NO:16 siRNA RNA or modifications thereof, SEQ ID NO:17 (g) for the antisense strand sequence of either the sense strand sequence of SEQ ID NO:18 siRNA RNA or modifications thereof, SEQ ID NO:19 (h) for the antisense strand sequence of either the sense strand sequence of SEQ ID NO:20 siRNA RNA or modifications thereof, SEQ ID NO:21 (i) for the antisense strand sequence of either the sense strand sequence of SEQ ID NO:22 siRNA RNA or modifications thereof, and, SEQ ID NO:23 (j) for the antisense strand sequence of either the sense strand sequence of SEQ ID NO:24 siRNA RNA or modifications thereof, selected from the group consisting of 1 2 or one of the one or more RNA or modified siRNA siRNA and/or modifications of RNA and a combination thereof, any one of claims 1-4 pharmaceutical composition.
[claim6]
6. Wherein said modification is RNA, 2 '- O, 4' -C methylene bridge locked LNA having modified nucleotides, 2 '- methoxy nucleotide, 2' - methoxyethoxy nucleotide, or combinations thereof, at least one modified nucleotide 2 characterized in that, in any one of claims 2-5 pharmaceutical composition.
[claim7]
7. Wherein the tumor, brain, breast cancer, colon cancer, prostate cancer, liver cancer, lung cancer, leukemia, lymphoma and cervical cancer is selected from the group consisting of characterized in that, in any one of claims 1-6 of the pharmaceutical composition.
[claim8]
8. Wherein the brain cancer, glioblastoma and characterized in that, a pharmaceutical composition according to claim 7.
[claim9]
9. Wherein the tumor is characterized in that the early cancer, any one of claims 1-8 pharmaceutical composition.
[claim10]
10. Wherein the nucleic acid, drug delivery and included in the material, any one of claims 1-9 pharmaceutical composition.
[claim11]
11. A nucleic acid of the following: 5 (a) for the antisense strand sequence SEQ ID NO:6 consists of a sequence of the sense strand siRNA sequence or modified RNA, (b) for the antisense strand sequence SEQ ID NO:7 of the sense strand siRNA sequence SEQ ID NO:8 or modified RNA, 9 sequence (c) for the antisense strand sequence of either the sense strand sequence of SEQ ID NO:10 siRNA RNA or modifications thereof, 11 (d) for the antisense strand sequences to a sequence number of the sense strand siRNA sequence 12 or modified RNA, 13 (e) for the antisense strand sequences to a sequence number of the sense strand siRNA sequence 14 or modified RNA, (f) for the antisense strand sequence SEQ ID NO:15 of either the sense strand sequence of SEQ ID NO:16 siRNA RNA or modifications thereof, SEQ ID NO:17 (g) for the antisense strand sequence of either the sense strand sequence of SEQ ID NO:18 siRNA RNA or modifications thereof, SEQ ID NO:19 (h) for the antisense strand sequence of either the sense strand sequence of SEQ ID NO:20 siRNA RNA or modifications thereof, SEQ ID NO:21 (i) for the antisense strand sequence of either the sense strand sequence of SEQ ID NO:22 siRNA RNA or modifications thereof, as well as, (j) for the antisense strand sequence SEQ ID NO:23 of either the sense strand sequence of SEQ ID NO:24 siRNA RNA or modifications thereof, the anti-tumor is selected from the group consisting of nucleic acid.
[claim12]
12. Wherein said modification is RNA, 2 '- O, 4' -C methylene bridge locked LNA having modified nucleotides, 2 '- methoxy nucleotide, 2' - methoxyethoxy nucleotide, or a combination thereof, at least one modified nucleotide 2 characterized in that, according to claim 11 antitumoral nucleic acid.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NAGOYA CITY UNIVERSITY
  • NAGOYA UNIVERSITY
  • 発明者(英語)
  • KONDO YUTAKA
  • DEGUCHI SHOUICHI
  • NATSUME ATSUSHI
  • KATSUSHIMA KEISUKE
国際特許分類(IPC)
指定国 (WO201803988)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close